Company intelligence / Profile preview

Nido felice

Watertown, Massachusetts, United Statesvinted.fr ↗

Ownership: Private
Development stage: Other

Overview

NIDO-361, a small molecule allosteric modulator of the androgen receptor, is in Phase 2 clinical trials for SBMA/Kennedy’s disease. The trial has completed enrollment of 54 patients across Europe, UK, and South Korea. The company also has early-stage programs targeting neurodegeneration via novel mechanisms identified through its proprietary functional genomics platform. Orphan Drug Designation was granted by EMA in October 2024.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eli Lilly & Company (investor)collaborations with academic leaders in neurology

Beyond the preview

Go deeper on Nido felice.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nido felice.

Explore the full profile